secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001140361-24-041663
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant sells Dermavant to Organon for up to $1.2B in cash plus royalties
-------------------------------------------------------------------------

- Total consideration up to ~$1.2B: $175M at closing, $75M milestone on FDA approval for atopic dermatitis, up to $950M in net sales milestones.
- Tiered royalties: low-to-mid single-digit % on net sales up to $1B, 30% on net sales above $1B; all paid pro rata to Dermavant equity holders.
- Roivant owns ~87% of Dermavant; merger expected to close Q4 2024, subject to HSR and antitrust conditions.
- Organon will assume Dermavant's existing revenue interest purchase and funding agreements at closing.
- Merger approved by Dermavant and Roivant boards and by shareholders holding at least 75% voting rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/0001140361-24-041663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/ny20036156x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-041663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer